Anupam Rasayan Rs 760-cr IPO to open on Mar 12; issue price at Rs 553-555

Specialty chemical company Anupam Rasayan on Monday fixed a price band of Rs 553-555 a share for its Rs 760-crore initial share-sale, which will open for public subscription on March 12

IPO
Axis Capital, Ambit Private, IIFL Securities, and JM Financial are the merchant bankers for the issue
Press Trust of India New Delhi
2 min read Last Updated : Mar 08 2021 | 1:26 PM IST

Specialty chemical company Anupam Rasayan on Monday fixed a price band of Rs 553-555 a share for its Rs 760-crore initial share-sale, which will open for public subscription on March 12.

The three-day public issue will close on March 16,Anupam Rasayan said in a statement.

The IPO aggregating up to Rs 760 crore is entirely fresh issuance of equity shares and proceeds of the issue would be mainly used to pay debt.

The Surat-based company has reserved about 2.20 lakh shares for employees. Half of the issue is reserved for qualified institutional buyers, 35 per cent for retail investors and 15 per cent for non-institutional bidders.

Anupam Rasayan commenced operations in 1984 with conventional products and now it makes speciality chemicals that involve multi-step synthesis and complex chemistries.

It has six multi-purpose manufacturing facilities based in Gujarat with a combined aggregate installed capacity of around 23,396 metric tonnes, of which 6,726 metric tonnes was added in March 2020.

The company mainly caters to the agrochemical, personal care and pharmaceutical sectors, which accounted for over 95 per cent of its revenues in 2019-20. Its clients include Syngenta Asia Pacific, Sumitomo Chemical Company and UPL Limited.

The company's revenue from operations increased by 45 per cent to Rs 539.22 crore in the nine months ended December 31, 2020 from Rs 371.80 crore in the corresponding year-ago period.

Axis Capital, Ambit Private, IIFL Securities and JM Financial are merchant bankers for the issue.

The company, which filed preliminary papers for the IPO with the regulator in December, obtained its go ahead in February.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IPOsIndian stock marketschemicals companies

First Published: Mar 08 2021 | 1:13 PM IST

Next Story